All In Biotech

Drug Trial Radar · NCT06878066

Thrombolysis in Factor Xa-inhibitors Trial

The Efficacy and Safety of Intravenous Thrombolysis in Acute Ischemic Stroke Patients With Recent Ingestion of Factor Xa-inhibitors Trial (SIFT)

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Mar 14, 2025

Primary completion

Dec 31, 2028

Study completion Dec 31, 2037

Sponsor

Lead sponsor
Guri HagbergAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Klinbeforsk; Clinical Trial Unit (CTU), Oslo University Hospital
First posted
Mar 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study looks at whether stroke patients who take FXa inhibitors (a type of blood thinner) can safely receive clot-busting treatment (IVT). IVT is a common emergency treatment for stroke, but current guidelines say it should not be given to people who have taken FXa inhibitors in the last 48 hours. This is because doctors worry that IVT might cause dangerous bleeding in the brain. However, new research suggests that IVT might be safe for these patients. Some studies even show that stroke patients on FXa inhibitors who receive IVT do not have a higher risk of brain bleeding than other stroke patients. But because these studies were not designed as full medical trials, doctors still avoid IVT for this group. The SIFT trial will compare two groups of stroke patients who take FXa inhibitors: One group will receive IVT to see if it helps them recover better. One group will not receive IVT, which is the current standard. Doctors will check if IVT helps with recovery and if it causes any serious bleeding. If IVT is found to be safe and effective, this study could change stroke treatment guidelines and help more patients get life-saving care. Right now, some guidelines say that stroke patients on FXa inhibitors should have a blood test before getting IVT, to measure how much of the drug is in their system. But these tests are not available in most hospitals, and waiting for results could delay important treatment. The SIFT trial will not require this test before giving IVT. More and more people use FXa inhibitors to prevent strokes, but right now, they are being denied IVT based on old rules. If this study proves that IVT is safe for them, it could help doctors give better care to thousands of stroke patients.

Conditions

  • Stroke
  • Stroke (in Patients With Atrial Fibrillation)
  • Ischemic Stroke
  • Acute Ischemic Stroke
  • Anticoagulant Therapy
  • Factor Xa Inhibitor
  • Intracranial Hemorrhages
  • Hemorrhagic Transformation Due to Acute Stroke
  • Bleeding in the Brain

Interventions

  • thrombolysis therapyDrug

    All treatment and monitoring routines are according to the hospitals' standard operating procedures (SOP), and both drugs (Alteplase (ALP) and Tenecteplase (TNK)) are approved drugs for the indication AIS with similar efficacy and safety profile. SIFT is designed to test the hypothesis that intravenous thrombolysis (IVT) (tenecteplase 0.25 mg/kg or alteplase 0.9 mg/kg intravenously) is efficient and safe in acute ischemic stroke patients (AIS) with recent ingestion (last 48 hours) of an Factor Xa (FXa) inhibitor who otherwise are eligible for IVT.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Early neurological improvement (ENI)Time frame: 24 hours (22-36 h).

Locations

21 sites in 3 countries. Site status is shown where the registry gives one.

  • Dept. of Neurology, Aalborg Universitetshospital

    Aalborg, Aalborg, Denmark · Recruiting

  • Dept of Neurology Aarhus University Hospital

    Aarhus, Aarhus N, Denmark · Recruiting

  • Dept of Medicine, Helse More and Romsdal Health Trust, Aalesund Hospital

    Ålesund, Norway · Recruiting

  • Dept of Medicine, Haraldsplass deaconal Hospital

    Bergen, Norway · Recruiting

  • Dept. Of Neurology, Haukeland University Hopsital

    Bergen, Norway · Recruiting

  • Dept of Neurology, Drammen Hospital Trust

    Drammen, Norway · Recruiting

  • Dept of Neurology, Ostfold Hospital Trust, Kalnes

    Grålum, Norway · Recruiting

  • Dept of Neurology, Hospital of Southern Norway, SSHF

    Kristiansand, Norway · Recruiting

  • Dept of Neurology, Innlandet Hospital Trust, Lillehammer

    Lillehammer, Norway · Recruiting

  • Dept. of Neurology, Oslo University Hospital

    Oslo, Norway · Recruiting

  • Dept of Neurology, Stavanger University Hospital

    Stavanger, Norway · Recruiting

  • Dept of Neurology, Vesfold Hospital Trust, Tonsberg

    Tønsberg, Norway · Recruiting

  • Dept. of Neurology, Tromso University Hospital

    Tromsø, Norway · Recruiting

  • Dept. Of Medicine, St.Olav Hospital, Trondheim

    Trondheim, Norway · Recruiting

  • Dept. of Medicine, Baerum Hospital

    Baerum, Gjettum, Norway · Recruiting

  • Dept of Neurology Danderyd Hospital

    Stockholm, Danderyd, Sweden · Recruiting

  • Dept of Neurology , Lund University Hospital

    Lund, Lund, Sweden · Recruiting

  • Dept of Neurology, Stroke Unit Skåne University Hospital

    Malmö, Malmö, Sweden · Recruiting

  • Dept of Neurology, Karolinska University Hospital

    Stockholm, Stockholm County, Sweden · Recruiting

  • Dept of Neurology Norrland University Hospital

    Umeå, Umeå, Sweden · Recruiting

  • Dept of Neurology, Uppsala University Hospital

    Uppsala, Uppsala County, Sweden · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.